Ind-Swift Limited (INDSWFTLTD.BO)
INR 13.05
(-0.84%)
INR 13.05
(-0.84%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 946.56 Million INR | -33.16% |
| 2022 | 1.4 Billion INR | 13.56% |
| 2021 | 1.24 Billion INR | -0.17% |
| 2020 | 1.24 Billion INR | 12.43% |
| 2019 | 1.1 Billion INR | -5.6% |
| 2018 | 1.17 Billion INR | 20.46% |
| 2017 | 972.7 Million INR | -30.56% |
| 2016 | 1.4 Billion INR | -43.18% |
| 2015 | 2.46 Billion INR | 106.11% |
| 2014 | 1.19 Billion INR | -7.11% |
| 2013 | 1.28 Billion INR | 9.75% |
| 2012 | 1.17 Billion INR | 0.0% |
| 2010 | 861.54 Million INR | 20.93% |
| 2009 | 712.43 Million INR | 13.25% |
| 2008 | 629.07 Million INR | 2.53% |
| 2007 | 613.57 Million INR | 26.99% |
| 2006 | 483.16 Million INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 269.94 Million INR | -4.62% |
| 2023 FY | 942.4 Million INR | -33.16% |
| 2023 Q4 | 283 Million INR | 32.72% |
| 2023 Q3 | 213.23 Million INR | -56.35% |
| 2023 Q2 | 488.5 Million INR | 5.78% |
| 2023 Q1 | 461.82 Million INR | 436.09% |
| 2022 Q4 | 86.14 Million INR | -81.02% |
| 2022 Q3 | 453.79 Million INR | 4.82% |
| 2022 Q2 | 432.93 Million INR | -0.92% |
| 2022 Q1 | 436.96 Million INR | 26744.45% |
| 2022 FY | 1.4 Billion INR | 13.56% |
| 2021 Q3 | 447.47 Million INR | 9.38% |
| 2021 Q1 | 386.32 Million INR | 133.65% |
| 2021 Q2 | 409.1 Million INR | 5.9% |
| 2021 FY | 1.24 Billion INR | -0.17% |
| 2021 Q4 | -1.64 Million INR | -100.37% |
| 2020 FY | 1.24 Billion INR | 12.43% |
| 2020 Q1 | 296.6 Million INR | 1723.25% |
| 2020 Q2 | 372.16 Million INR | 25.48% |
| 2020 Q3 | 402.04 Million INR | 8.03% |
| 2020 Q4 | 165.34 Million INR | -58.87% |
| 2019 FY | 1.1 Billion INR | -5.6% |
| 2019 Q3 | 407.59 Million INR | 11.28% |
| 2019 Q4 | -18.27 Million INR | -104.48% |
| 2019 Q1 | 350.58 Million INR | 288.63% |
| 2019 Q2 | 366.27 Million INR | 4.48% |
| 2018 FY | 1.17 Billion INR | 20.46% |
| 2018 Q3 | 341.77 Million INR | -6.22% |
| 2018 Q4 | 90.21 Million INR | -73.61% |
| 2018 Q2 | 364.45 Million INR | -8.7% |
| 2018 Q1 | 399.19 Million INR | 4755.36% |
| 2017 Q4 | -8.57 Million INR | -102.69% |
| 2017 Q1 | 333.82 Million INR | 125.94% |
| 2017 FY | 972.7 Million INR | -30.56% |
| 2017 Q3 | 319.13 Million INR | 0.0% |
| 2016 Q1 | 463.18 Million INR | -53.96% |
| 2016 Q3 | 2.06 Billion INR | 121.43% |
| 2016 Q2 | 933.44 Million INR | 101.53% |
| 2016 Q4 | -1.28 Billion INR | -162.25% |
| 2016 FY | 1.4 Billion INR | -43.18% |
| 2015 FY | 2.46 Billion INR | 106.11% |
| 2015 Q2 | 422.83 Million INR | 14.51% |
| 2015 Q4 | 1 Billion INR | 127.2% |
| 2015 Q3 | 442.81 Million INR | 4.73% |
| 2015 Q1 | 369.27 Million INR | 3542.13% |
| 2014 Q2 | 372.18 Million INR | 20.94% |
| 2014 FY | 1.19 Billion INR | -7.11% |
| 2014 Q4 | -10.72 Million INR | -101.86% |
| 2014 Q3 | 576.23 Million INR | 54.82% |
| 2014 Q1 | 307.75 Million INR | 349.41% |
| 2013 Q2 | 426.93 Million INR | -6.77% |
| 2013 FY | 1.28 Billion INR | 9.75% |
| 2013 Q1 | 457.91 Million INR | 6.61% |
| 2013 Q3 | 376.77 Million INR | -11.75% |
| 2013 Q4 | 68.47 Million INR | -81.82% |
| 2012 Q4 | 429.54 Million INR | -10.33% |
| 2012 FY | 1.17 Billion INR | 0.0% |
| 2012 Q1 | - INR | 0.0% |
| 2012 Q2 | 425.06 Million INR | 0.0% |
| 2012 Q3 | 479.01 Million INR | 12.69% |
| 2010 FY | 861.54 Million INR | 20.93% |
| 2009 FY | 712.43 Million INR | 13.25% |
| 2008 FY | 629.07 Million INR | 2.53% |
| 2007 FY | 613.57 Million INR | 26.99% |
| 2006 FY | 483.16 Million INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 99.386% |
| NATCO Pharma Limited | 10.05 Billion INR | 90.589% |
| Suven Pharmaceuticals Limited | 1.4 Billion INR | 32.522% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -0.442% |
| Achyut Healthcare Limited | 1.6 Million INR | -58729.521% |
| Ajanta Pharma Limited | 30.46 Billion INR | 96.893% |
| Alkem Laboratories Limited | 32.83 Billion INR | 97.117% |
| Alpa Laboratories Limited | 156.14 Million INR | -506.202% |
| Alembic Pharmaceuticals Limited | 15.86 Billion INR | 94.035% |
| AstraZeneca Pharma India Limited | 2.6 Billion INR | 63.599% |
| Aurobindo Pharma Limited | 39.23 Billion INR | 97.587% |
| Bajaj HealthCare Limited | 985.34 Million INR | 3.935% |
| Bliss GVS Pharma Limited | 1.41 Billion INR | 33.304% |
| Brooks Laboratories Limited | 51.18 Million INR | -1749.486% |
| Divi's Laboratories Limited | 14.17 Billion INR | 93.32% |
| Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 99.013% |
| Eris Lifesciences Limited | 4.94 Billion INR | 80.85% |
| FDC Limited | 5.34 Billion INR | 82.302% |
| Glenmark Pharmaceuticals Limited | 67.56 Billion INR | 98.599% |
| Glenmark Life Sciences Limited | 11.64 Billion INR | 91.868% |
| Granules India Limited | 7.18 Billion INR | 86.821% |
| Gufic Biosciences Limited | 1.07 Billion INR | 12.169% |
| Hester Biosciences Limited | 908.84 Million INR | -4.151% |
| Indoco Remedies Limited | 4.74 Billion INR | 80.067% |
| Ind-Swift Laboratories Limited | 2.12 Billion INR | 55.439% |
| Ipca Laboratories Limited | 13.91 Billion INR | 93.197% |
| Jagsonpal Pharmaceuticals Limited | 773.41 Million INR | -22.389% |
| Krebs Biochemicals & Industries Limited | 46.15 Million INR | -1950.799% |
| Lasa Supergenerics Limited | 291.17 Million INR | -225.086% |
| Laurus Labs Limited | 3.01 Billion INR | 68.561% |
| Lupin Limited | 95.67 Billion INR | 99.011% |
| Mankind Pharma Limited | 23.15 Billion INR | 95.912% |
| Medicamen Biotech Limited | 335.16 Million INR | -182.417% |
| Medico Remedies Limited | 161.84 Million INR | -484.864% |
| Megasoft Limited | 49.52 Million INR | -1811.176% |
| Piramal Pharma Limited | 19.91 Billion INR | 95.247% |
| RPG Life Sciences Limited | 1.63 Billion INR | 42.124% |
| Sigachi Industries Limited | 579.88 Million INR | -63.233% |
| Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 69.235% |
| Unichem Laboratories Limited | 6.72 Billion INR | 85.926% |
| Wanbury Limited | 1.16 Billion INR | 18.465% |
| Windlas Biotech Limited | 1 Billion INR | 5.956% |
| ZIM Laboratories Limited | 1.01 Billion INR | 6.563% |
| Zydus Lifesciences Limited | 43.17 Billion INR | 97.808% |
| Procter & Gamble Health Limited | 2.99 Billion INR | 68.399% |
| Amrutanjan Health Care Limited | 1.09 Billion INR | 13.869% |
| Bal Pharma Limited | 389.89 Million INR | -142.778% |
| Strides Pharma Science Limited | 9.16 Billion INR | 89.669% |
| Venus Remedies Limited | 1.91 Billion INR | 50.604% |
| Aarti Pharmalabs Limited | 3.07 Billion INR | 69.211% |
| Nectar Lifesciences Limited | 625.55 Million INR | -51.318% |
| Shilpa Medicare Limited | 2.18 Billion INR | 56.591% |
| Aarti Drugs Limited | 1.16 Billion INR | 18.922% |
| IOL Chemicals and Pharmaceuticals Limited | 1.09 Billion INR | 13.854% |
| Suven Life Sciences Limited | 109.75 Million INR | -762.476% |
| Valiant Laboratories Limited | 36.28 Million INR | -2508.413% |
| J. B. Chemicals & Pharmaceuticals Limited | 8.41 Billion INR | 88.754% |
| Solara Active Pharma Sciences Limited | 4.57 Billion INR | 79.331% |
| Themis Medicare Limited | 782.85 Million INR | -20.912% |
| Hikal Limited | 2.48 Billion INR | 61.929% |
| Torrent Pharmaceuticals Limited | 21.42 Billion INR | 95.581% |
| Sequent Scientific Limited | 2.9 Billion INR | 67.38% |
| Novartis India Limited | 470.1 Million INR | -101.354% |
| Wockhardt Limited | 6.4 Billion INR | 85.21% |
| Jubilant Pharmova Limited | 14.45 Billion INR | 93.451% |
| Biofil Chemicals and Pharmaceuticals Limited | 16.2 Million INR | -5739.51% |
| Neuland Laboratories Limited | 2.92 Billion INR | 67.691% |
| Morepen Laboratories Limited | 1.98 Billion INR | 52.373% |
| Kilitch Drugs (India) Limited | 412.42 Million INR | -129.511% |
| Mangalam Drugs & Organics Limited | 676.14 Million INR | -39.994% |